S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
Unique BioPharma Opportunity for Accredited Investors (Ad)
A collection of the insights Warren Buffett offered in his annual letter Saturday
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
Unique BioPharma Opportunity for Accredited Investors (Ad)
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
Macron booed by French farmers who blame him for not doing enough to support agriculture
Unique BioPharma Opportunity for Accredited Investors (Ad)
MILAN FASHION PHOTOS: Ferragamo, Dolce&Gabbana conceal and reveal, balance transparency with cover
Tax-free status of movie, music and games traded online is on table as WTO nations meet in Abu Dhabi
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
Unique BioPharma Opportunity for Accredited Investors (Ad)
A collection of the insights Warren Buffett offered in his annual letter Saturday
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
Unique BioPharma Opportunity for Accredited Investors (Ad)
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
Macron booed by French farmers who blame him for not doing enough to support agriculture
Unique BioPharma Opportunity for Accredited Investors (Ad)
MILAN FASHION PHOTOS: Ferragamo, Dolce&Gabbana conceal and reveal, balance transparency with cover
Tax-free status of movie, music and games traded online is on table as WTO nations meet in Abu Dhabi
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
Unique BioPharma Opportunity for Accredited Investors (Ad)
A collection of the insights Warren Buffett offered in his annual letter Saturday
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
Unique BioPharma Opportunity for Accredited Investors (Ad)
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
Macron booed by French farmers who blame him for not doing enough to support agriculture
Unique BioPharma Opportunity for Accredited Investors (Ad)
MILAN FASHION PHOTOS: Ferragamo, Dolce&Gabbana conceal and reveal, balance transparency with cover
Tax-free status of movie, music and games traded online is on table as WTO nations meet in Abu Dhabi
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
Unique BioPharma Opportunity for Accredited Investors (Ad)
A collection of the insights Warren Buffett offered in his annual letter Saturday
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
Unique BioPharma Opportunity for Accredited Investors (Ad)
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
Macron booed by French farmers who blame him for not doing enough to support agriculture
Unique BioPharma Opportunity for Accredited Investors (Ad)
MILAN FASHION PHOTOS: Ferragamo, Dolce&Gabbana conceal and reveal, balance transparency with cover
Tax-free status of movie, music and games traded online is on table as WTO nations meet in Abu Dhabi
OTCMKTS:CSLLY

CSL (CSLLY) Stock Price, News & Analysis

$93.77
+0.07 (+0.07%)
(As of 02/23/2024 ET)
Today's Range
$93.60
$94.68
50-Day Range
$89.91
$99.41
52-Week Range
$71.51
$105.11
Volume
23,345 shs
Average Volume
32,616 shs
Market Capitalization
$90.60 billion
P/E Ratio
N/A
Dividend Yield
1.27%
Price Target
N/A

CSL MarketRank™ Stock Analysis

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
0.00% of Shares Sold Short
Dividend Strength
Weak
Based on Four Factors
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
14.29%
From $3.15 to $3.60 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.84 out of 5 stars


CSLLY stock logo

About CSL Stock (OTCMKTS:CSLLY)

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants. The CSL Seqirus segment provides influenza related products and pandemic services to governments. The CSL Vifor segment offers products in the therapeutic areas of iron deficiency and nephrology. The company also licenses CSL intellectual property. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia.

CSLLY Stock Price History

CSLLY Stock News Headlines

Wilsons downgrades CSL (CMXHF) to a Hold
Unique BioPharma Opportunity for Accredited Investors
LexaGene is poised to disrupt a market with an estimated annual TAM of ~$2.0B
CSL share price on watch amid 20% profit jump
CSL Says 1H Profit Rises, Boosts Dividend -- Update
Unique BioPharma Opportunity for Accredited Investors
LexaGene is poised to disrupt a market with an estimated annual TAM of ~$2.0B
CSL Profit Rises, Boosts Dividend
Are CSL shares set for an earnings boost?
All hands on deck for employee growth at CSL
CSL worker held for 'spying' on Navy ship
QURE Jan 2024 25.000 call
QURE Jan 2024 5.000 call
QURE Jan 2024 25.000 put
QURE Jan 2024 9.000 call
QURE Jan 2024 9.000 put
See More Headlines
Receive CSLLY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CSL and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
2/24/2024
Fiscal Year End
6/30/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
OTCMKTS:CSLLY
Employees
32,000
Year Founded
1904

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$13.31 billion
Cash Flow
$3.14 per share
Book Value
$18.48 per share

Miscellaneous

Free Float
N/A
Market Cap
$90.60 billion
Optionable
Not Optionable
Beta
0.74
7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

  • Dr. Paul F. McKenzie Ph.D. (Age 58)
    MD, CEO & Executive Director
    Comp: $2.75M
  • Ms. Joy Carolyn Linton B.Com. (Age 59)
    BComm, GAICD, Grad Dip AFI, Chief Financial Officer
    Comp: $2.05M
  • Mr. Mark Dehring
    Head of Investor Relations
  • Mr. Gregory Boss B.S. (Age 63)
    BS(Hons), J.D., Executive VP of Legal & General Counsel
    Comp: $1.1M
  • Christina Hickie
    Senior Manager of Communications
  • Ms. Roanne Parry
    Chief Human Resources Officer
  • Dr. Karen Etchberger (Age 66)
    Executive Vice President of Quality & Business Services
    Comp: $1.03M
  • Ms. Jemimah Brennan
    Head of Communications - Asia Pacific
  • Dr. Andrew D. Nash BSc (Hons) (Age 62)
    GAICD, Ph.D., Senior Vice President of Research
  • Dr. William Mezzanotte M.D. (Age 65)
    M.P.H., Executive VP & Head of Research and Development
    Comp: $1.46M

Should I Buy CSL Stock? CSLLY Pros and Cons Explained

These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of CSL was last updated on Wednesday, February 21, 2024 at 2:36 PM.














CSLLY Stock Analysis - Frequently Asked Questions

How have CSLLY shares performed in 2024?

CSL's stock was trading at $97.17 at the beginning of 2024. Since then, CSLLY shares have decreased by 3.5% and is now trading at $93.77.
View the best growth stocks for 2024 here
.

Are investors shorting CSL?

CSL saw a drop in short interest in the month of January. As of January 15th, there was short interest totaling 9,800 shares, a drop of 59.2% from the December 31st total of 24,000 shares. Based on an average trading volume of 71,700 shares, the days-to-cover ratio is presently 0.1 days.
View CSL's Short Interest
.

Is CSL a good dividend stock?

CSL (OTCMKTS:CSLLY) pays an annual dividend of $1.19 per share and currently has a dividend yield of 1.27%.
Read our dividend analysis for CSLLY.

How do I buy shares of CSL?

Shares of CSLLY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:CSLLY) was last updated on 2/25/2024 by MarketBeat.com Staff